文献速递骨肌介入US

超声引导下注射治疗与手术神经切除术治疗莫顿神经瘤的成本效益分析

Ultrasound-Guided Injection Treatments Versus Surgical Neurectomy for Morton Neuroma: A Cost-Effectiveness Analysis.
PubMed 文献 · AJR Am J Roentgenol · 2021-09-15

采用决策分析模型,对保守治疗失败的莫顿神经瘤患者比较直接手术神经切除术与三种先行超声引导注射(激素、酒精、激素/酒精序贯)策略,以及不治疗策略。基础分析中激素/酒精序贯注射策略占优,增量成本效果比为4401.61美元/QALY;概率敏感性分析中该策略在10000次模拟中74%支持。结论:先行超声引导注射治疗相较于直接手术更具成本效益。

要点

  • 对保守治疗失败的莫顿神经瘤,先行超声引导注射治疗比直接手术神经切除术更具成本效益。
  • 激素/酒精序贯选择性注射策略在基础分析中占优,增量成本效果比为4401.61美元/QALY(对比不治疗)。
  • 当酒精注射治疗成功概率降至40%以下时,选择性激素注射策略成为最具成本效益的方案。

核心结论

  • 对保守治疗失败的莫顿神经瘤患者,先行超声引导注射治疗相较于直接手术神经切除术是一种成本效益策略;超声引导注射治疗被列为一线治疗指征。

研究设计与样本

  • 增量成本效用分析,采用决策分析模型,对保守治疗失败的莫顿神经瘤假设患者群体比较直接手术神经切除术与三种选择性注射策略(选择性激素注射、选择性酒精注射、选择性激素/酒精序贯注射)及不治疗策略;模型参数来自文献、报销数据库和专家意见;时间跨度3年,社会成本视角,支付意愿阈值100000美元/QALY;对关键模型参数进行敏感性分析。

诊断标准与关键数值

  • 基础输入值下,激素/酒精选择性注射策略占优,与不治疗相比增量成本效果比为4401.61美元/QALY;概率敏感性分析在10000次模拟试验中74%支持该策略;当酒精注射治疗成功概率降至40%以下时,选择性激素注射策略成为最具成本效益。

临床应用与阅片要点

  • 作者结论认为,对保守治疗失败的莫顿神经瘤患者,先行超声引导注射治疗相较于直接手术神经切除术具有成本效益;超声引导注射治疗被列为一线治疗指征。

局限性

  • 模型参数(包括治疗成本、效果、并发症率和健康效用状态)来自文献、报销数据库和专家意见。
  • 结果对大多数输入参数敏感性低,但当酒精注射治疗成功概率降至40%以下时,最具成本效益的策略变为选择性激素注射。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Morton neuroma is a common, painful disorder of the foot with multiple treatment options of varying cost and effectiveness. OBJECTIVE. The aim of this study was to determine the most cost-effective treatment pathway for symptomatic Morton neuromas when conservative management has failed. METHODS. An incremental cost-utility analysis was performed comparing a direct to surgical neurectomy strategy with three selective injection strategies in which one or more ultrasound-guided injection therapies was tried first before surgery for patients who did not respond to treatment. The three selective injection strategies were selective steroid injection, selective alcohol injection, and selective steroid/alcohol injection in which both steroid injections and alcohol sclerosing injections were trialed successively before surgical neurectomy. The direct-to-surgery approach was compared with the three different selective injection strategies and with a no-treatment strategy in a decision-analytic model for a hypothetical group of patients with symptomatic Morton neuroma in whom conservative management had failed. Model parameters, including treatment costs, effectiveness, complication rates, and health utility states, were estimated from the literature, reimbursement databases, and expert opinion. The outcome was cost per quality-adjusted life year (QALY) with a time horizon of 3 years. A societal cost perspective was adopted with a willingness-to-pay threshold of $100,000/QALY. Sensitivity analyses for key model parameters were performed. RESULTS. For the base input values, the steroid/alcohol selective injection strategy was dominant and yielded an incremental cost-effectiveness ratio of $4401.61/QALY compared with no treatment. The probabilistic sensitivity analysis supported this strategy in 74% of 10,000 simulated trials. Results were robust with low sensitivity to most input parameters. However, when the probability of successful alcohol injection treatment dropped below 40%, the steroid selective injection strategy became most cost-effective. CONCLUSION. A trial of ultrasound-guided injection therapies for Morton neuroma is a cost-effective strategy compared with proceeding directly to surgical neurectomy. CLINICAL IMPACT. Ultrasound-guided injection therapies are indicated as first-line treatment of patients with symptomatic Morton neuromas when conservative management fails.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Ross AB, Jacobs A, Williams KL, et al. Ultrasound-Guided Injection Treatments Versus Surgical Neurectomy for Morton Neuroma: A Cost-Effectiveness Analysis. AJR Am J Roentgenol. 2021. PMID: 34523955. doi:10.2214/AJR.21.26419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。